Patient-focused care and research, clinical trials in #Genitourinary cancers #GU #Prostate #Kidney #Bladder #GermCell. @HuntsmanCancer @UUtah
Joined November 2020
- Tweets898
- Following244
- Followers787
- Likes1.1K
GU Cancer Research Program @HuntsmanCancer retweeted
Just in @JAMANetworkOpen 👉 Our paper on real-world pts w/ mHSPC (mAPMS) #prostatecancer ➡️ Direct AR inhibitors (Apa/enza) associated with/ ⬆️ OS vs abiraterone (median OS 67.9 vs 57.2 mo; HR 0.74) 👉 link: shorturl.at/et4G7 @PCFnews @urotoday @umangtalking @neerajaiims
GU Cancer Research Program @HuntsmanCancer retweeted
Out now in @JCO_ASCO and @CircAHA: Our @American_Heart & @ASCO joint scientific statement on defining cardiovascular (CV) endpoints in oncology trials👉a framework for asking CV safety questions before trials begin👉Article link in the last post 👇#CardioOncology #CardioTwitter. @OncoAlert @US_FDA
🤖 Made with AI
GU Cancer Research Program @HuntsmanCancer retweeted
Breaking new👉 today @US_FDA approved capivasertib (oral AKT inhibitor) for the metastatic HSPC/APMS #prostatecancer with PTEN deficiency👉personalized medicine continues to leap forward👉Capitello-281 ph3 trial summary👇 @OncoAlert @urotoday @AUC3_Official
PTEN as a prognostic marker and clinical decision tool in #mHSPC: Multidisciplinary discussion. @Daniel_J_George, Neal Shore, MD, FACS, David Morris, MD, FACS & @neerajaiims review the CAPItello-281 Phase III trial, highlighting PTEN loss as a critical prognostic marker identifying a high-risk subset of patients with metastatic hormone-sensitive #ProstateCancer. #WatchNow > bit.ly/4slFxqL
GU Cancer Research Program @HuntsmanCancer retweeted
Incredibly proud to see our trainee Zeynep @ziremozay match at @YaleIMed ! Her hard work, resilience, and commitment to excellence have truly paid off. A well-deserved achievement. Congratulations! #Match2026 @OncoAlert
I’m going to Yale!! #Match2026
Still can’t believe I matched at my #1 choice @YaleIMed
I'm so grateful to my mentors, friends, and family for supporting me every step of the way and believing in me!
@neerajaiims @umangtalking @montypal @maughanonc @NazliDizman @ReneeSaliby
GU Cancer Research Program @HuntsmanCancer retweeted
Thank you @ASCO #DailyNews for highlighting abs #676 #705 exploring RW Rx patterns and outcomes following 1L EV/pembro #bladdercancer Survival outcomes are limited. 2L after EV/pembro remains an area of unmet need ➡️ tinyurl.com/mbk6r88c @urotoday @OncoAlert @neerajaiims
GU Cancer Research Program @HuntsmanCancer retweeted
Breaking news from @ASCO #GU26 👉Adding belzutifan to adjuvant pembrolizumab significantly improves disease free survival (HR: 0.72)👉Congrats @drchoueiri & team for changing SOC again in pts with #kidneycancer @kidneycan @OncoAlert @urotoday
GU Cancer Research Program @HuntsmanCancer retweeted
Just in @JournalCancer 👉patient-level data from ph3 trials👉clear OS/PFS benefit with apalutamide in advanced #prostatecancer but no differences by race👉Rigorous equity-focused evidence that matters @ggebraelmd @Soum_Roy_RadOnc bit.ly/4s79qep @OncoAlert @urotoday
GU Cancer Research Program @HuntsmanCancer retweeted
Truly humbled by the support of colleagues across the American Society of Clinical Oncology (@ASCO) global community. Thank you for the trust and encouragement—I’m deeply grateful and excited to serve. @OncoAlert @urotoday @OncBrothers @montypal @DrChoueiri @DrRanaMcKay
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!
GU Cancer Research Program @HuntsmanCancer retweeted
Just in @TheLancetOncol 👉Ph3 CYCLONE 2: Abemaciclib + abiraterone vs. abi did not improve rPFS (primary endpoint) in mCRPC #ProstateCancer. Higher-risk pts (M1 at dx, Gleason ≥8, ⬆️PSA) seem to benefit more @OncoAlert @urotoday @PCF_Science Link👉 bit.ly/43HvEZJ
GU Cancer Research Program @HuntsmanCancer retweeted
Join us today, Monday, October20th, 8.30-10 am, #ESMO25 Berlin👉for the “special symposium” on personalization of treatment in metastatic #ProstateCancer based on biomarkers👉Talk titles & Location info/map👇@OncoAlert @urotoday @PCF_Science
GU Cancer Research Program @HuntsmanCancer retweeted
Breaking news from #ESMO25 in Berlin 👉Randomized trial of Pluvicto/Lu-177 vs. docetaxel (DOC) in 199 pts with mCRPC #prostatecancer 👉progressing after ARPI therapy👉Similar PFS (primarily endpoint) but higher OS with docetaxel👇#KimChi #ESMO25 @OncoAlert @urotoday @PCF_Science
GU Cancer Research Program @HuntsmanCancer retweeted
🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 bit.ly/47lt5Oj @PCFnews @OncoAlert @urotoday
GU Cancer Research Program @HuntsmanCancer retweeted
Just in @JAMANetworkOpen 👉 In pt level data from two ph3 trials (n=2187) 👉statin use associated with ⬆️ OS in advanced #prostatecancer treated with apalutamide. Congrats @ziremozay and @Soum_Roy_RadOnc Free access👉 bit.ly/3HI1ZYJ @PCFnews @urotoday @OncoAlert
GU Cancer Research Program @HuntsmanCancer retweeted
A beautiful manuscript from @nsayeghmd & @ziremozay w mentorship from @neerajaiims @huntsmancancer & @TiansterZhang @utswcancer - must read for anyone interested in #ProstateCancer! @mzugman @SalvadorjcMD @EbrahimiHedyeh @ReginaBarCar @NazliDizman
👉🏻Just in @JCO_ASCO: We explore how biomarker-driven, rational combos may unlock ICI potential in mCRPC #prostatecancer 👇🏻 Plus data showing responses in MMRD, HRD, or high inflammatory infiltrates @neerajaiims @TiansterZhang @ziremozay @OncoAlert bit.ly/3UHqw2W
GU Cancer Research Program @HuntsmanCancer retweeted
👉🏻Just in @JCO_ASCO: We explore how biomarker-driven, rational combos may unlock ICI potential in mCRPC #prostatecancer 👇🏻 Plus data showing responses in MMRD, HRD, or high inflammatory infiltrates @neerajaiims @TiansterZhang @ziremozay @OncoAlert bit.ly/3UHqw2W
GU Cancer Research Program @HuntsmanCancer retweeted
Congrats @siadaneshmand @AndreaNecchi 👉 Striking results in @JCO_ASCO from Ph2b #SunRISe-1 trial in pts w/BCG-unresponsive high-risk NMIBC #bladdercancer treated w/ TAR-200 monoRx ➡️~83% CR, with >2 yrs median response, ~13% Grade ≥3 TRAEs ➡️ tinyurl.com/4t2ywny9 @urotoday
GU Cancer Research Program @HuntsmanCancer retweeted
Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
Just in👉Two @TheLancetOncol papers on patient-reported QOL results in ph3 TALAPRO-2 trial👉in all-comer & HRR deficient mCRPC #ProstateCancer pts👉Improved OS without compromising QOL👇Links: bit.ly/3DWHlSR & bit.ly/3E3SSQi @urotoday @OncoAlert @PCFnews 👇
GU Cancer Research Program @HuntsmanCancer retweeted
🎙 @neerajaiims of @huntsmancancer and Dr. Jeanny Aragon-Ching of @InovaSchar highlight key innovations in GU cancer research from #ASCO25 on a new episode of the #ASCODailyNews Podcast: bit.ly/4elzewZ
GU Cancer Research Program @HuntsmanCancer retweeted
A novel west-African germline founder mutation in HOXB13 (p.X285Kext) increases risk of high-grade prostate cancer but also enhances sensitivity to hormonal therapy. Congrats to PCF-funded Mayuko Kanayama 👏 @neerajaiims @PCFnews @urotoday @EdEsplin nature.com/articles/s41391-0…
GU Cancer Research Program @HuntsmanCancer retweeted
Excited to see our work published in @CCR_AACR ! Real-world pts w/ mHSPC #prostatecancer w/ HRRalt had worse survival than those w/ non-altered HRR 👉bit.ly/3TsOw9i👇
Grateful for terrific support from team @RyonGraf @umangtalking @neerajaiims @urotoday @OncoAlert
Just in @CCR_AACR 👉Congrats @chadihcmd @umangtalking & @Huntsman_GU team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 @flatironhealth @FoundationATCG @RyonGraf 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i @OncoAlert @urotoday
